Identification of Novel Inhibitors of the Transforming Growth Factor β1 (TGF-β1) Type 1 Receptor (ALK5)
作者:James F. Callahan、Joelle L. Burgess、James A. Fornwald、Laramie M. Gaster、John D. Harling、Frank P. Harrington、Jag Heer、Chet Kwon、Ruth Lehr、A. Mathur、Barbara A. Olson、Joseph Weinstock、Nicholas J. Laping
DOI:10.1021/jm010493y
日期:2002.2.1
Screening of our internal compound collection for inhibitors of the transforming growth factor beta1 (TGF-beta1) type I receptor (ALK5) identified several hits. Optimization of the dihydropyrroloimidazole hit 2 by introduction of a 2-pyridine and 3,4-methylenedioxyphenyl group gave 7, a selective ALK5 inhibitor. With this information, optimization of the triarylimidazole hit 8 gave the selective inhibitor 14, which inhibits TGF-beta1-induced fibronectin mRNA formation while displaying no measurable cytotoxicity in the 48 h XTT assay.